Abstract 1133
Background
Immune checkpoint inhibitors are an important therapy. However, their essence is nonspecific and efficiency of single usage is not satisfactory. The mutant neoantigen specific T (Nas-T) cell, as an adoptive cell treatment, is a specific immunotherapy for each individual. Our previous research has proved that the combined immunotherapy of mutant Nas-T cell and PD1 antibody is more effective than PD1 alone in prolonging PFS (World Conference on Lung Cancer 2018). We aim to evaluate the characteristics of the immune repertoire (IR) as a predictive biomarker for immunotherapy and to construct personalized and specific TCR-T.
Methods
14 patients with advanced solid tumors who failed after multiline treatments were recruited. They were divided into durable clinical benefit (complete response, partial response or stable disease for more than 3 months) and non-durable clinical benefit (DCB and NCB) based on PFS. Peripheral blood was collected at baseline and each cycle. IR-seq of the CDR3 regions of human TCRβ chains was used to interrogate the TCRs frequency. We used single neoantigen to stimulate the infused T cells and performed RNAseq for the sorted CD137(+) cells to obtain the full-length TCR α and β chain. Lastly, we constructed TCR-T cells via transfecting the TCR α/β pair into the T cells of patients and co-cultured with neoantigen to analyze the functionality of TCRs.
Results
After neoantigen pulsing, the clonality of infused T cells pool significantly increased (P = 0.0001), suggesting some tumor-specific T-cells were expanded and enriched after neoantigen pulsing. Compared to baseline, T-cell repertoire of NCB and DCB after 1st cycle displayed significant changes: Shannon 1.19 vs 0.97 (P = 0.002); clonality 0.68 vs 1.19 (P = 0.001). Elevated clonality may indicate expanded tumor-specific T-cells which could recognize mutant neoantigen specifically. Besides, based on the in vitro TCR-T experiments, the constructed TCR-T cells can specifically recognize the mutant neoantigen and lyse the target cells expressing the corresponding neoantigen.Table:
1228P
Neoantigen Sequence | HLA-I typing | TCR Vα | TCR Vβ | |||
---|---|---|---|---|---|---|
Gene name | Sequence* | All V Hits With Score# | Clonal Sequence# | All V Hits With Score# | Clonal Sequence# | |
MTAP/SPINK1 Fused Gene | VLLPRHMKV | A0201 | TRAV35 (574.6) | TGTGCTGGGTATGGCTCTAGCAA CACAGGCAAACTAATCTTT | TRBV19 (646.8) | TGTGCCAGTCGGACAGGGGGA TCACCCCTCCACTTT |
FER | NYVSNVSKF | A2301 | TRAV29DV5 (667.6) | TGTGCAGCTTCAACTGGGGCAAA CAACCTCTTCTTT | TRBV7-2 (626.7) | TGTGCCAGCACCTCTGCCCCC TCCTACGAGCAGTACTTC |
SPINK1 | FLLSALALL | B4403 | TRAV20 (589.1) | TGTGCTGTTCCCCTGGGAACAGG CTTTCAGAAACTTGTATTT (response to neoantigen) | TRBV21-1 (557.8) | TGTGCCAGCAGCAAAGACCCT AGCGGGAATCAAGAGACCCAGTACTTC |
CLCN6 | ALIGAAASL | B6701 | TRAV19 (612.4) | TGTGCTCTTCTGAATTATGGTGGTGC TACAAACAAGCTCATCTTT | TRBV6-5 (675.4) | TGTGCCAGCAGTGGGACAGCCAATGA GCAGTTCTTC (response to neoantigen) |
MTAP | AESFMFRTW | C0401 | TRAV38-2DV8 (658.4) | TGTGCTTATTGGGAGCTTGTCTCTGGGG CTGGGAGTTACCAACTCACTTTC | TRBV5-1 (637.6) | TGCGCCAGCAGCTTGACTAGCGGGGGG TTCTACGAGCAGTACTTC |
TAP1 | RLSLFLALV | C0702 | TRAV16 (622.2) | TGTGCTCCCTGGGCCCTAGGAGGAGG TGCTGACGGACTCACCTTT | TRBV30 (403.4) | TGTGCCTGGAGTGTAACAGGGGGC AAAGCAGATACGCAGTATTTT |
MAN2C1 | FLQGRNFFL |
Conclusions
The mutant Nas-T cell is a personalized immunotherapy. IR is a potential predictive biomarker.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shunchang Jiao.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract